Press releases

September 17, 2026

Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)

Read more

September 02, 2026

Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome

Read more

September 01, 2026

Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease

Read more

August 25, 2026

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

August 19, 2026

Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)

Read more

August 04, 2026

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

Read more

July 28, 2026

Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update

Read more

July 24, 2026

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

July 08, 2026

Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact

Read more

June 19, 2026

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more